Emkay Broker Research reports

Stovekraft logged healthy ~12% revenue growth (vs 3% decline at larger peer TTK Prestige), which was in line with the company’s guidance of sustained 8-10% revenue outperformance vs the underlying industry.

SPRL delivered a healthy ~11% YoY consolidated revenue growth, outpacing the underlying industry’s low-single digit production growth by ~3%, though EBITDA margin at ~20.1% was ~68bps lower than our estimates (dragged by higher other expenses).

ONGC’s Q3FY25 SA EBITDA came in at Rs170.4bn, a 4% beat to our estimate, mainly led by higher-than-expected revenues. RPAT at Rs82.4bn was a 4% miss on higher DD&A; and lower other income.

GHCL’s Q3 EBITDA at Rs2.3bn (+53% YoY/+9% QoQ) was above our estimates largely due to operational efficiency resulting in cost savings (volumes are flat YoY/QoQ).

KBL reported an 11% PAT miss in 3Q at Rs2.8bn, due to lower margins – down by 21bps QoQ to 3% (partly due to change in penal interest recognition), and other income, as the bank adopted a calibrated growth approach amid rising liquidity/cost pressures.

Pricol reported a soft Q3 revenue performance (~5% miss), partially impacted by supply issues, which are seen normalizing from Q1FY26.

We maintain BUY on Voltamp Transformers (VAMP) with unchanged TP of Rs13,350. VAMP’s Q3FY25 revenue/EBITDA came in at Rs4.8bn/Rs990mn (+18%/+21% YoY).

We upgrade SRF to BUY from Add and raise our SoTP-based TP by over 19% to Rs3,100, as we believe i) the worst is behind for all of its businesses, ii) SRF is seeing gradual uptick in its specialty chemical business from existing products, and healthy contribution is expected from new AIs in FY26

TTMT’s Q3 performance was below expectations driven by sequential ASP decline at JLR and standalone operations, as well as lower than expected margin expansion in JLR (JLR margin up by 244bps QoQ to 14.2%, consolidated margin stable at 11.5%)

Star Health reported weak performance for Q3FY25, with GWP growth at 5.3% (at a 1.8% miss) impacted by implementation of the 1/n regulation and Combined Ratio at 103.3% vs our estimate of 100.5% driven by higher Claims and Expense Ratio (affected by 1/n premium accounting of long-term policies).